Dulaglutide
Dulaglutide is a pharmaceutical drug with 76 clinical trials. Currently 7 active trials ongoing. Historical success rate of 96.7%.
Success Metrics
Based on 58 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
14
Mid Stage
38
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
96.7%
58 of 60 finished
3.3%
2 ended early
7
trials recruiting
76
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Clinical Trials (76)
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
A Study of HS-20094 in Patients With T2DM
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 76